Zymeworks Inc.

Zymeworks Inc. is a global biotechnology company dedicated to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company's mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. Utilizing proprietary molecular modeling software and therapeutic platforms, Zymeworks focuses on developing advanced protein therapeutics. While incorporated in Delaware, its corporate head office is located in Vancouver, British Columbia, Canada.

Zymeworks' pipeline primarily targets oncology, with an expanding focus on autoimmune and inflammatory diseases. Its lead clinical candidate, zanidatamab (marketed as Ziihera®), is a HER2-targeted bispecific antibody currently undergoing multiple global clinical trials for HER2-expressing cancers. Zanidatamab has received FDA Breakthrough Therapy and Fast Track designations. The company's therapeutic platforms, including Azymetric™, EFECT™, and ProTECT™, enable the engineering of highly differentiated antibody-based therapeutics, such as bispecific antibodies and antibody-drug conjugates (ADCs). Other product candidates in development include ZW191, ZW220, ZW209, and ZW1528, addressing various solid tumors and chronic obstructive pulmonary disease.

In recent news, Zymeworks presented new Phase 1 data for its folate receptor alpha-targeting ADC, ZW191, at the ESMO Gynaecological Cancers Congress in June 2026. May 2026 saw the publication of Phase 3 HERIZON-GEA-01 data for Ziihera® (zanidatamab-hrii) in The New England Journal of Medicine, demonstrating a durable survival benefit in first-line HER2+ gastroesophageal adenocarcinoma. The company also announced a share repurchase program of up to $125 million in May 2026. Leadership appointments in early 2026 included Kristin Stafford as Chief Financial Officer, Adam Schayowitz as Executive Vice President and Head of Research & Development, and Scott Platshon as Executive Vice President and Chief Business Officer. Kenneth Galbraith serves as the CEO and Chair. Zymeworks is strategically focused on optimizing future cash flows through internal innovation, licensing, and strategic acquisitions, leveraging royalty and milestone payments from partnered products.